Adimab
North America, New Hampshire, United States, Lebanon
Description
Adimab is an antibody discovery and optimization platform, developing full-length human Immunoglobulin Gs.
Investor Profile
Adimab has backed more than 2 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 1 exits across its portfolio.
Investment Focus Highlights
- Concentrates on Series A, Series C rounds (top funding stages).
- Majority of deals are located in United States.
- Strong thematic focus on Biotechnology, Pharmaceutical, Therapeutics.
Stage Focus
- Series A (50%)
- Series C (50%)
Country Focus
- United States (100%)
Industry Focus
- Biotechnology
- Pharmaceutical
- Therapeutics
FAQ
Frequently Asked Questions
Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.
Who does Adimab frequently co-invest with?
What are some of recent deals done by Adimab?
Find More Investors Like Adimab
Discover similar investors in our database and build your perfect investor list.
Need help with your fundraising strategy?Read our fundraising guides
